Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Roche to commercialize Hepatitis C drug in China with Ascletis

Swiss drugmaker Roche Holding AG said it had teamed up with biotech firm Ascletis to develop and commercialize its investigative drug danoprevir in China for the treatment of the Hepatitis-C virus.

Published
15 April 2013
From
Yahoo! News
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C

Sofosbuvir Would Form Basis of First All-Oral Regimen for HCV Genotype 2 and 3 Patients, and Interferon-Sparing Regimen for Genotype 1 Patients.

Published
09 April 2013
From
Gilead press release
Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C

Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 and BMS' investigational NS5A replication complex inhibitor daclatasvir.

Published
08 April 2013
From
Vertex press release
Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C

Filing Based on Phase 3 Data in Treatment-Naïve and Treatment-Experienced Patients with Compensated Liver Disease.

Published
02 April 2013
From
Janssen press release
Hepatitis C drug goes after patients’ RNA

The new drug, called miravirsen, binds to microRNA-122, sequesters it and indirectly thwarts viral replication, says study coauthor Harry Janssen, a hepatologist and physician at the University of Toronto. Janssen and colleagues report the findings March 27 in the New England Journal of Medicine.

Published
28 March 2013
From
Science News
'Sponge' Drug Shows Promise For Treating Hepatitis C

One of the drugs in the pipeline, called miravirsen, may be able to stop the virus with little side effects, doctors from University Health Network in Toronto, Canada, reported Wednesday.

Published
28 March 2013
From
NPR (blog)
Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

A planned review by the study's Data and Safety Monitoring Board (DSMB) of safety data from 200 patients in all four arms and of SVR4 rates (sustained virologic response four weeks after completion of therapy) from 100 patients in the two 12-week duration arms concluded that the trial should continue without modification.

Published
26 March 2013
From
Gilead press release
Sofosbuvir plus ribavirin works well for hard-to-treat inner-city hepatitis C patients

A simple 24-week oral regimen consisting of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 hepatitis C, many of whom had

Published
20 March 2013
By
Liz Highleyman
AbbVie interferon-free combinations cure most newly treated hepatitis C patients

All-oral regimens consisting of the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to sustained response for more than 90% of previously untreated hepatitis 

Published
20 March 2013
By
Liz Highleyman
Presidio Pharmaceuticals Announces Collaboration with Boehringer Ingelheim

The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio’s HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C.

Published
13 March 2013
From
Presidio press release

Filter by country